Exabis Library
Welcome to the e-CCO Library!
P673: Microbial diversity in newly diagnosed treatment naïve Inflammatory Bowel Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P673: The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P673: Trends in inflammatory bowel disease infections and vaccinations in the past four decades - a high-level text mining analysis of PubMed publications.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P673: Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P674 Monitoring posologic change in adalimumab intensification dosing regimen from 40 mg every week to 80 mg every other week
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P674: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P674: Clinical characteristics and management of Crohn’s disease in patients with residual disease after surgery compared with curative surgery: Results from PRACTICROHN study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P674: Definition of a microbial signature as a predictor of anti-TNFα treatment response
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P674: Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in paediatric Crohn's disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P674: Predictors of response to biologics in Crohn's Diseases: A population-based study from the epi-IIRN
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P674: Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P675 CT-Scout platform, the digital solution to boost patient recruitment in inflammatory bowel disease clinical trials: A multicentre prospective observational comparative study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P675: Associations between Inflammatory Bowel Disease, social isolation, and mortality: evidence from UK Biobank cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P675: Flavonoid-degrading bacteria have central positions in correlation network analysis in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P675: Follow-up ileocolonoscopy is underused in Crohn’s disease patients after ileocecal resection despite higher total and inpatient health care costs compared with controls without resection
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P675: Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis – 54 week data
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P675: Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P675: The relationship between gender, severity of disease, treatment type, and employment outcome in patients with inflammatory bowel disease in Israel
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P676 Faecal monitoring is useful in monitoring treatment response in anti-TNF-treated patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P676: Burden of depression and anxiety among inflammatory bowel disease patients in a national cohort in Israel – Data from the EPI-IIRN
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM